IDBiomedicalCorporatePresentation.pptVIP

Pneumococcal Immunization in the Elderly U.S. Burden of Pneumococcal Disease in the Elderly Invasive disease (IPD = bacteremia, pneumonia with bacteremia, uncommonly meningitis) 38 / 100,000 person years Mortality = 7.2 / 100,000 persons years Disproportionate impact among Blacks Increased rate in patients with DM, cardio-pulmonary disease, solid tumors, EtOH abuse. Community-acquired pneumonia (CAP) 350 - 620,000 hospitalizations per year in elderly 20-60% pneumococcal (25-30% best estimate) Impact of Conjugate Vaccine in the Elderly Impact of Conjugate Vaccine in the Elderly IPD in the elderly has dropped sharply in conjugate era, but some subsets show less marked effect. Absolute rate of pneumonias with invasive disease and non-conjugate serotypes has increased 11.6% Evidence Regarding Pneumococcal Vaccines in the Elderly Invasive pneumococcal disease: No compelling evidence from RCTs (low power), Meta-analyses are heterogeneous and still underpowered, but Observational cohort and case-control studies monotonously show 45-65% efficacy and are really the basis of current recommendations. Community-acquired pneumonia: No evidence from RCT Observational studies are heterogeneous, but often (not always) are quite underpowered Meta-analyses aren’t helpful. Cost-Effectiveness 23-PS vaccine is generally believed to be acceptably cost-effective in the elderly. Multiple analyses in different countries Typically acceptably cost-effective, in some cases cost-saving; but critically dependent on assumptions. Earlier analyses more dramatic, but assumed efficacy against pneumococcal CAP, More recent estimates reverse this trend and focus on IPD, but still show acceptable cost-effectiveness even considering IPD costs alone. ID Biomedical Approach to Pneumococcal Vaccine ID Biomedical candidate is a chimeric protein representing immunodominant and surface-exposed domains of two conserved pneumococcal proteins. Current configuration is a aluminum-adjuvanted injectable. P